TLSITriSalus Life Sciences Inc. Common Stock

TriSalus Life Sciences (NASDAQ:TLSI) outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity’s Global Growth Conference, with management emphasizing the company’s pressure-enabled delivery technology for solid-tumor treatments. President and CEO M

TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, represe

TriSalus Life Sciences Inc (TLSI) reiterates full-year guidance as reimbursement breakthrough in office-based labs and robust clinical pipeline position the company for accelerated back-half growth.

TriSalus Life Sciences Inc (TLSI) navigates commercial growth and FDA delays while showcasing improved margins and robust clinical data.

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M

Moby summary of TriSalus Life Sciences, Inc.'s Q1 2026 earnings call

TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of +12.50% and -15.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

TriSalus Life Sciences Inc. (NASDAQ:TLSI) is one of the best fast growing penny stocks to buy right now. On May 4, TriSalus Life Sciences initiated patient enrollment for the PREDICTT clinical trial, a prospective study evaluating its proprietary Pressure-Enabled Drug Delivery/PEDD technology in patients with primary or metastatic liver tumors. Conducted at The University of […]

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -4.55% and -0.55%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?